Thursday, March 28, 2013
Wilms tumor 1 is overexpressed in many different cancers, but most
antibody and small molecule developers have deemed it undruggable because it is
an intracellular transcription factor. Now, researchers at Eureka Therapeutics Inc. and the Memorial Sloan-Kettering Cancer Center have targeted Wilms tumor 1-positive cancer cells with
a mAb against peptide fragments derived from the protein that are presented on
the cells' surface.1
The case for mAbs
Although companies and academics have
advanced other immunotherapy candidates to treat WT1-positive cancers as far as
Phase II trials, Liu and Scheinberg both think a therapeutic mAb will have
utility because it offers the potential to treat patients with active disease.
SciBX 6(12); doi:10.1038/scibx.2013.279
Published online March 28, 2013
1. Dao, T. et al. Sci.
Transl. Med.; published online March 13, 2013;
Contact: David A. Scheinberg, Memorial Sloan-Kettering Cancer
Center, New York, N.Y.
Contact: Cheng Liu, Eureka Therapeutics Inc., Emeryville, Calif.
2. Pinilla-Ibarz, J. et
al. Leukemia 20, 2025-2033 (2006)
3. Gomez-Nunez, M. et
al. Leuk. Res. 30, 1293-1298 (2006)
4. Maslak, P.G. et al.
Blood 116, 171-179 (2010)
AND INSTITUTIONS MENTIONED
Eureka Therapeutics Inc., Emeryville, Calif.
Formula Pharmaceuticals Inc., Berwyn, Pa.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Inovio Pharmaceuticals Inc. (NYSE-M:INO), Blue Bell, Pa.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Osaka University Graduate School of Medicine, Osaka, Japan
Sloan-Kettering Institute, New York, N.Y.